Today: 8 February 2026
Subscribe
Browse Category

NYSE:BMY News 21 December 2025 - 5 February 2026

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb shares rose 1.7% to $58.58 by midday Thursday, bucking a broader market decline, after the company issued a 2026 outlook projecting up to $47.5 billion in revenue. Quarterly revenue increased 1% to $12.5 billion, with growth portfolio sales up 16% and legacy drugs down 15%. The company expects Eliquis sales to rise despite U.S. price negotiations, but warned of a potential $2 billion drop in 2027 when European patents expire.
5 February 2026
··
Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft shares fell 1.1% to $454.52 in after-hours trading Tuesday, tracking a broad tech selloff as tariff concerns rattled markets. Bristol Myers Squibb announced a partnership to use Microsoft’s AI radiology tools for early lung cancer detection. Investors are awaiting Microsoft’s fiscal Q2 earnings on Jan. 28 for updates on cloud and AI growth. The S&P 500 closed down 2.04%, Nasdaq off 2.38%.
20 January 2026
···
Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia dropped 3.4% to $179.83, dragging AI stocks lower as U.S. markets fell on tariff threats from President Trump over Greenland. The Nasdaq lost 1.6% and S&P 500 slid 1.3% in early trading. Morgan Stanley downgraded IT hardware, citing weak demand and high costs. Microsoft, Broadcom, and Palantir also declined, while AMD rose 1.3%.
20 January 2026
············
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb shares jumped 4.2% to $56.72 after UBS upgraded the stock to “buy” and raised its price target to $65. UBS cited upcoming catalysts but noted ongoing patent-expiry pressure through 2028. Trading volume exceeded averages as the stock outperformed peers on a down market day. Investors await the company’s Jan. 12 J.P. Morgan conference appearance and Feb. 5 quarterly results.
8 January 2026
·
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics shares closed 2025 up 3.5% at $63.54 after FDA cleared Myqorzo for obstructive hypertrophic cardiomyopathy. The drug, set to launch in January under a REMS program and boxed warning, will compete with Bristol Myers Squibb’s Camzyos. Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 each on Dec. 29 under a pre-arranged plan. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
····
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb shares fell 0.7% to $54.27 in thin year-end trading Monday, underperforming the broader U.S. market. Investors are watching the Jan. 2 shareholder record date for its next dividend and the Feb. 5 earnings report. Peers were mixed, with Eli Lilly up and Pfizer down. Low volumes and year-end rebalancing drove volatility, according to traders.
29 December 2025
···
Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers Squibb shares closed down 0.1% at $54.64 Friday, trading in a narrow range as year-end positioning and Fed rate signals dominated market focus. The company’s next investor event is its fourth-quarter results call on Feb. 5. Thin holiday trading volume heightened volatility across sectors. The S&P 500 hovered near 7,000, with investors watching for signs of momentum shifts.
29 December 2025
·
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb closed Friday at $54.64, down 0.13%, with after-hours indications at $54.75 late Saturday. Institutional filings showed Brookstone Capital Management and Cwm LLC increased stakes, while Meyer Handelman Co. reduced holdings. The stock sits in the middle of its $42.52–$63.33 52-week range. Analyst consensus remains mixed, with an average price target near $53.93.
28 December 2025
·
Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb shares closed Friday at $54.65, little changed, and edged up to $54.72 after hours. The stock is down about 3% for 2025, trading near the lower end of its yearly range. Recent headlines focused on institutional position changes and year-end market conditions, with light news flow as U.S. markets head into the weekend.
27 December 2025
···
Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb (BMY) closed Friday at $54.64, down 0.13%, with after-hours trading near $54.72. Institutional filings showed mixed moves: Meyer Handelman Co. cut its stake by 9.9%, while Cwm LLC and Brookstone Capital Management increased holdings. No major company news released in the past 48 hours. Trading volume reached about 9.57 million shares.
27 December 2025
·
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb closed at $54.71 on Dec. 24, 2025, after trading between $54.20 and $54.75, with a 52-week range of $42.52 to $63.33. The company agreed to provide Eliquis free to Medicaid starting in 2026 and will donate over seven tons of Eliquis API to the U.S. government. BMS also announced steep discounts for several drugs and secured three years of tariff relief.
25 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb closed at $54.71 on Dec. 24, up 0.79%, with after-hours trading flat at $54.70 amid thin holiday volume. The NYSE session ended early for Christmas Eve. Analysts cited by MarketBeat maintained a “Hold” consensus and average 12-month target near current levels. No major company news moved the stock.
25 December 2025
··
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended Tuesday, December 23, 2025, slightly lower in regular trading, then steadied after the closing bell as investors digested a fresh legal headline tied to U.S. drug pricing—plus a growing list of end‑of‑year catalysts that could shape sentiment into 2026. BMY finished the session at $54.26, down $0.41 (-0.74%), and traded modestly higher in extended hours at about $54.36 (+0.20%) as of the evening update. MarketBeat After-hours snapshot: where BMY stands tonight Even with the post-close bounce, Tuesday’s tape looked like a classic pre-holiday setup: a narrow move, lighter conviction, and investors focusing more on
24 December 2025
·
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) stock is back in the spotlight on Tuesday, December 23, 2025, as investors weigh a fast-moving U.S. drug-pricing landscape, fresh legal headlines tied to Medicare negotiations, and new analyst commentary on competitive pressure in a key growth product category. At the same time, Bristol Myers is heading into 2026 with a higher dividend, a defined near-term calendar (including a February earnings date), and intensifying debates over whether the stock’s “value” profile is a bargain—or a reflection of policy risk and the post-patent “reset” that still hangs over Big Pharma. BMY stock price today (December 23,
23 December 2025
··
Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb Company (NYSE: BMY) ended Monday’s regular session on a modestly stronger note, then held near flat in after-hours trading as investors continued to weigh a fast-evolving U.S. drug-pricing landscape, BMS’s Eliquis-focused policy commitments, and a fresh dividend hike headed into 2026. Below is what’s moving BMY after the bell on December 22, 2025, and the key items investors will be watching into Tuesday’s open (Dec. 23)—including the latest headlines, Wall Street forecasts, and the open questions that could drive the next leg up or down. BMY stock after the bell: where shares closed and how after-hours trading looks
23 December 2025
··
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
1 2

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Go toTop